The Outlook for Immunotherapies

During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with mismatch repair proficient advanced endometrial cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.

According to a recent analysis, preliminary circulating tumor DNA kinetics could serve as an early pharmacodynamic biomarker, offering potential for early biologic proof of concept.